DOCSLIB.ORG

Respiratory Chain Complex I Deficiency Caused by Mitochondrial DNA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Respiratory Chain Complex I Deficiency Caused by Mitochondrial DNA European Journal of Human Genetics (2011) 19, 769–775 & 2011 Macmillan Publishers Limited All rights reserved 1018-4813/11 www.nature.com/ejhg ARTICLE Respiratory chain complex I deficiency caused by mitochondrial DNA mutations Helen Swalwell1, Denise M Kirby2, Emma L Blakely1, Anna Mitchell1, Renato Salemi2,6, Canny Sugiana2,3,7, Alison G Compton2, Elena J Tucker2,3, Bi-Xia Ke2, Phillipa J Lamont4, Douglass M Turnbull1, Robert McFarland1, Robert W Taylor1 and David R Thorburn*,2,3,5 Defects of the mitochondrial respiratory chain are associated with a diverse spectrum of clinical phenotypes, and may be caused by mutations in either the nuclear or the mitochondrial genome (mitochondrial DNA (mtDNA)). Isolated complex I deficiency is the most common enzyme defect in mitochondrial disorders, particularly in children in whom family history is often consistent with sporadic or autosomal recessive inheritance, implicating a nuclear genetic cause. In contrast, although a number of recurrent, pathogenic mtDNA mutations have been described, historically, these have been perceived as rare causes of paediatric complex I deficiency. We reviewed the clinical and genetic findings in a large cohort of 109 paediatric patients with isolated complex I deficiency from 101 families. Pathogenic mtDNA mutations were found in 29 of 101 probands (29%), 21 in MTND subunit genes and 8 in mtDNA tRNA genes. Nuclear gene defects were inferred in 38 of 101 (38%) probands based on cell hybrid studies, mtDNA sequencing or mutation analysis (nuclear gene mutations were identified in 22 probands). Leigh or Leigh-like disease was the most common clinical presentation in both mtDNA and nuclear genetic defects. The median age at onset was higher in mtDNA patients (12 months) than in patients with a nuclear gene defect (3 months). However, considerable overlap existed, with onset varying from 0 to 460 months in both groups. Our findings confirm that pathogenic mtDNA mutations are a significant cause of complex I deficiency in children. In the absence of parental consanguinity, we recommend whole mitochondrial genome sequencing as a key approach to elucidate the underlying molecular genetic abnormality. European Journal of Human Genetics (2011) 19, 769–775; doi:10.1038/ejhg.2011.18; published online 2 March 2011 Keywords: respiratory chain; complex I; mitochondrial DNA; mutation; genetic counselling INTRODUCTION NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV1, Isolated complex I deficiency is the most frequently observed mito- NDUFV2, NDUFA2 and NDUFA11), 1 of the 2 chromosome X chondrial respiratory chain disorder, and is associated with a wide genes encoding complex I subunits (NDUFA1) and 9 autosomal range of clinical presentations, including marked and often fatal lactic genes encoding proteins involved in complex I assembly, namely acidosis, cardiomyopathy, leukoencephalopathy, pure myopathy and NDUFAF1 (CIA30), NDUFAF2 (B17.2L), NDUFAF3, NDUFAF4, hepatopathy with tubulopathy.1–3 Complex I deficiency is one of the C8orf38, C20orf7, NUBPL, FOXRED1 and ACAD9.10–16 Mutations in most common mitochondrial disorders of childhood; onset is usually nuclear genes involved in mtDNA maintenance, in particular POLG, early and death often occurs within the first year of life.4–7 which encodes the catalytic subunit of the mitochondrial polymerase Defining the molecular basis of complex I deficiency is a difficult g, may also cause isolated complex I deficiency in patients with Alpers’ task, not least because of the dual genetic control governing the correct syndrome.10 Equally, mutations have been identified in all seven of the assembly and function of complex I, but also as the largest complex in mtDNA genes encoding subunits of complex I,17 and also in mtDNA the mitochondrial respiratory chain, it is also the most intricate. tRNA (mt-tRNA) genes, particularly mitochondrial tRNALeu(UUR).2 Complex I is composed of 45 subunits,8 7 of which are encoded by The importance of mtDNA mutations as a potential molecular mitochondrial DNA (mtDNA), and the remaining 38 are nuclear aetiology for complex I deficiency was therefore not in doubt, but encoded. Moreover, a number of proteins are involved in the correct thus far their prevalence remained unclear. Indeed, it was previously processing and assembly of complex I, the total number of which as believed that complex I deficiency due to mtDNA mutations yet remains unknown.9 accounted for only 5–10% of paediatric complex I deficiency To date, pathogenic mutations in structural complex I proteins, cases.18,19 Recent screening of mitochondrial complex I subunit leading to complex I deficiency and associated with a disease pheno- genes has shown mutations in mtDNA accounting for a much higher type, have been identified in 21 nuclear genes: 11 of the 36 autosomal number of cases,20–27 and therefore, its screening is an essential step genes encoding complex I subunits (namely NDUFS1, NDUFS2, in the genetic diagnosis of complex I deficiency. Previous studies 1Mitochondrial Research Group, Institute for Ageing and Health, The Medical School, Newcastle University, Newcastle upon Tyne, UK; 2Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne, Victoria, Australia; 3Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia; 4Neurogenetic Unit, Department of Neurology, Royal Perth Hospital, Perth, Western Australia, Australia; 5Genetic Health Services Victoria, Royal Children’s Hospital, Melbourne, Victoria, Australia *Correspondence: Dr D Thorburn, Murdoch Childrens Research Institute, Royal Children’s Hospital, Flemington Road, Parkville, Victoria 3052, Australia. Tel: +613 8341 6235; Fax: +613 8341 6212; E-mail: [email protected] 6Current address: Peter MacCallum Cancer Centre, Melbourne, Australia. 7Current address: The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. Received 13 October 2010; revised 12 January 2011; accepted 14 January 2011; published online 2 March 2011 mtDNA mutations causing complex I deficiency HSwalwellet al 770 assessing the prevalence of nuclear gene mutations in complex I- NDUFS8 and NDUFV1 genes by denaturing HPLC, as described elsewhere.34 deficient paediatric cases have found the prevalence of these to also be Next-generation sequencing was also used to screen patients from 94 families for high. Three studies have reported mutations in nuclear genes encoding mutations in 103 genes. These included the 45 subunits, the 15 mt-tRNA genes subunits, assembly factors or related proteins in 20–25% of children flanking the complex I subunit genes, known assembly factors and genes that with complex I deficiency.15,28,29 shared an evolutionary relationship with complex I. The approach involved a discovery screen that sequenced PCR-amplified targets in pools of DNA obtained In this study, we report a detailed analysis of a large cohort of 109 from 20 patients, with each pool analysed in a single lane of an Illumina Genome patients, representing all patients diagnosed with childhood-onset Analyzer (Illumina, San Diego, CA, USA). Sequence variants were prioritised by complex I deficiency at a large national referral centre. We present bioinformatic analyses and assigned to individual patients by Sequenom geno- the identification of the underlying molecular basis of the enzyme typing (Sequenom, San Diego, CA, USA), followed by experimental studies to defects in a number of these patients, and have used these data to determine pathogenicity. The inclusion of 43 patients with known pathogenic estimate the prevalence of such mutations in these disorders and to mutations allowed us to determine a detection sensitivity of 78% for causal present data surveying the overall clinical findings in these patients. nuclear DNA variants and 28% for causal mtDNA variants; the latter figure was low because of highly variable amplification of mtDNA from different patients in PATIENTS AND METHODS the whole-genome amplification step before pooling.15 Patient cohort The cohort of 109 patients (from 101 families) represents all patients diagnosed RESULTS in Melbourne between 1992 and 2007, with definite childhood-onset mito- mtDNA mutations chondrial disease and an enzyme diagnosis of complex I deficiency. The Melbourne laboratory is referred almost all children from Australia and A total of 30 patients (from 29 families) were found to harbour a New Zealand who are biopsied for investigation of mitochondrial disease. pathogenic mutation in mtDNA (29% of probands), either in MTND Before biopsy, children had been referred to a geneticist or paediatrician subunit genes (21 probands from 22 families) or in MTTL1 or MTTW specialising in inborn errors of metabolism. Testing for metabolic or genetic tRNA genes (8 probands) (Table 1). Each of the mtDNA mutations conditions with phenotypes similar to mitochondrial disease would typically has been reported to be pathogenic in previous studies that provided have been performed (eg, organic acids, acylcarnitines, chromosome analysis), evidence to support pathogenicity such as sequence conservation, the but the extent of this testing varied. Histological and enzyme histochemical presence of lower levels of heteroplasmy in healthy maternal relatives analyses were routinely performed on muscle biopsies, but usually produced and either cybrid analysis or single-fibre PCR used to confirm an normal or equivocal results, as reported previously for patients with complex I association between heteroplasmic mutant load and mitochondrial deficiency.2 The criteria used
Load more

Recommended publications
  • High-Throughput, Pooled Sequencing Identifies Mutations in NUBPL And
    ARTICLES High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency Sarah E Calvo1–3,10, Elena J Tucker4,5,10, Alison G Compton4,10, Denise M Kirby4, Gabriel Crawford3, Noel P Burtt3, Manuel Rivas1,3, Candace Guiducci3, Damien L Bruno4, Olga A Goldberger1,2, Michelle C Redman3, Esko Wiltshire6,7, Callum J Wilson8, David Altshuler1,3,9, Stacey B Gabriel3, Mark J Daly1,3, David R Thorburn4,5 & Vamsi K Mootha1–3 Discovering the molecular basis of mitochondrial respiratory chain disease is challenging given the large number of both mitochondrial and nuclear genes that are involved. We report a strategy of focused candidate gene prediction, high-throughput sequencing and experimental validation to uncover the molecular basis of mitochondrial complex I disorders. We created seven pools of DNA from a cohort of 103 cases and 42 healthy controls and then performed deep sequencing of 103 candidate genes to identify 151 rare variants that were predicted to affect protein function. We established genetic diagnoses in 13 of 60 previously unsolved cases using confirmatory experiments, including cDNA complementation to show that mutations in NUBPL and FOXRED1 can cause complex I deficiency. Our study illustrates how large-scale sequencing, coupled with functional prediction and experimental validation, can be used to identify causal mutations in individual cases. Complex I of the mitochondrial respiratory chain is a large ~1-MDa ­assembly factors are probably required, as suggested by the 20 factors macromolecular machine composed of 45 protein subunits encoded necessary for assembly of the smaller complex IV9 and by cohort by both the nuclear and mitochondrial (mtDNA) genomes.
    [Show full text]
  • Analysis of Translating Mitoribosome Reveals Functional Characteristics of Translation in Mitochondria of Fungi
    ARTICLE https://doi.org/10.1038/s41467-020-18830-w OPEN Analysis of translating mitoribosome reveals functional characteristics of translation in mitochondria of fungi Yuzuru Itoh 1,2,4, Andreas Naschberger1,4, Narges Mortezaei1,4, Johannes M. Herrmann 3 & ✉ Alexey Amunts 1,2 1234567890():,; Mitoribosomes are specialized protein synthesis machineries in mitochondria. However, how mRNA binds to its dedicated channel, and tRNA moves as the mitoribosomal subunit rotate with respect to each other is not understood. We report models of the translating fungal mitoribosome with mRNA, tRNA and nascent polypeptide, as well as an assembly inter- mediate. Nicotinamide adenine dinucleotide (NAD) is found in the central protuberance of the large subunit, and the ATPase inhibitory factor 1 (IF1) in the small subunit. The models of the active mitoribosome explain how mRNA binds through a dedicated protein platform on the small subunit, tRNA is translocated with the help of the protein mL108, bridging it with L1 stalk on the large subunit, and nascent polypeptide paths through a newly shaped exit tunnel involving a series of structural rearrangements. An assembly intermediate is modeled with the maturation factor Atp25, providing insight into the biogenesis of the mitoribosomal large subunit and translation regulation. 1 Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, 17165 Solna, Sweden. 2 Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17165 Solna, Sweden. 3 Cell Biology, University
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • FOXRED1 (D-4): Sc-377010
    SANTA CRUZ BIOTECHNOLOGY, INC. FOXRED1 (D-4): sc-377010 BACKGROUND APPLICATIONS FOXRED1 (FAD-dependent oxidoreductase domain-containing protein 1), also FOXRED1 (D-4) is recommended for detection of FOXRED1 of human origin known as FP634, is a 486 amino acid single-pass membrane protein. Utilizing by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), FAD as a cofactor, FOXRED1 may act as a chaperone protein essential for the immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell function of mitochondrial complex I. Mutations to FOXRED1 may result in lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50- mitochondrial complex I deficiency (MT-C1D), which results in a wide range 1:500), immunohistochemistry (including paraffin-embedded sections) of clinical maladies from lethal neonatal disease to adult onset neurodegen- (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA erative disorders. Common phenotypes of MT-C1D include cardiomyopathy, (starting dilution 1:30, dilution range 1:30-1:3000). liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some Suitable for use as control antibody for FOXRED1 siRNA (h): sc-96988, forms of Parkinson disease. FOXRED1 exists as three alternatively spliced FOXRED1 shRNA Plasmid (h): sc-96988-SH and FOXRED1 shRNA (h) isoforms and is encoded by a gene mapping to human chromosome 11q24.2. Lentiviral Particles: sc-96988-V. With approximately 135 million base pairs and 1,400 genes, chromosome 11 makes up around 4% of human genomic DNA and is considered a gene and Molecular Weight of FOXRED1 isoform 1: 54 kDa.
    [Show full text]
  • NDUFA2 Rabbit Pab
    Leader in Biomolecular Solutions for Life Science NDUFA2 Rabbit pAb Catalog No.: A8136 Basic Information Background Catalog No. The encoded protein is a subunit of the hydrophobic protein fraction of the A8136 NADH:ubiquinone oxidoreductase (complex 1), the first enzyme complex in the electron transport chain located in the inner mitochondrial membrane, and may be involved in Observed MW regulating complex I activity or its assembly via assistance in redox processes. Mutations 11kDa in this gene are associated with Leigh syndrome, an early-onset progressive neurodegenerative disorder. Alternative splicing results in multiple transcript variants. Calculated MW 8kDa/10kDa Category Primary antibody Applications WB,IHC,IF Cross-Reactivity Human, Mouse, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 4695 O43678 IHC 1:50 - 1:100 Immunogen 1:50 - 1:200 IF Recombinant fusion protein containing a sequence corresponding to amino acids 1-95 of human NDUFA2 (NP_002479.1). Synonyms NDUFA2;B8;CD14;CIB8 Contact Product Information 400-999-6126 Source Isotype Purification Rabbit IgG Affinity purification [email protected] www.abclonal.com.cn Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using NDUFA2 antibody (A8136) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020). Exposure time: 30s. Immunohistochemistry of paraffin- Immunohistochemistry of paraffin- Immunofluorescence analysis of NIH/3T3 embedded human esophagus using embedded human liver cancer using cells using NDUFA2 antibody (A8136) at NDUFA2 antibody (A8136) at dilution of NDUFA2 antibody (A8136) at dilution of dilution of 1:100.
    [Show full text]
  • SI Materials and Methods Materials and Chemicals the DEP and PM Used in This Work Are the Standard Reference Material 2975 and S
    SI Materials and Methods Materials and chemicals The DEP and PM used in this work are the Standard Reference Material 2975 and Standard Reference Material 1648a, respectively, from the National Institute of Standards and Technology (NIST, USA). 1-nitropyrene, 1-nitrofluoranthene (BCR305), naphthalene (91489), fluoranthene (F807) and phenanthrene (P11409) were purchased from Sigma-Aldrich Co. LLC (USA). 6-hydroxynitropyrene (6-OHNP) and 8- hydroxynitropyrene (8-OHNP) were synthesized as previously described (1). Subject characterization We recruited 600 healthy volunteers from 3 cities with discrepant outdoor air pollution levels, including 100 male (mean age 65 years, range: 57-72 years) and 100 female (mean age 66 years, range: 56-72 years) in Zhangjiakou; 100 male (mean age 64 years, range: 57-71 years) and 100 female (mean age 64 years, range: 55-72 years) in Nanjing; as well as 100 male (mean age 66 years, range: from 60-73 years) and 100 female (mean age 64, range: 58-73) in Shijiazhuang. All volunteers were healthy non-smokers, free of any diagnosis of respiratory diseases, and lived in urban communities. Blood and mid-stream urine samples were collected between Dec.10th to Dec. 20th, 2014. For the panel study, we recruited 30 male (mean age 64 years, range: 58-71 years) and 30 female (mean age 65 years, range: 57-73 years) retired COPD patients in Nanjing; 30 male (mean age 65 years, range: 59-72 years) and 30 female (mean age 64 years, range: 57-71 years) retired COPD patients in Shijiazhuang. All subjects were living in urban communities and had been diagnosed with mild-to-moderate COPD in Nanjing Chest Hospital or the Second Hospital of Hebei Medical University according to the classification of Global Initiative for Chronic Obstructive Lung Disease (GOLD).
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Ykt6 Membrane-To-Cytosol Cycling Regulates Exosomal Wnt Secretion
    bioRxiv preprint doi: https://doi.org/10.1101/485565; this version posted December 3, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Ykt6 membrane-to-cytosol cycling regulates exosomal Wnt secretion Karen Linnemannstöns1,2, Pradhipa Karuna1,2, Leonie Witte1,2, Jeanette Kittel1,2, Adi Danieli1,2, Denise Müller1,2, Lena Nitsch1,2, Mona Honemann-Capito1,2, Ferdinand Grawe3,4, Andreas Wodarz3,4 and Julia Christina Gross1,2* Affiliations: 1Hematology and Oncology, University Medical Center Goettingen, Goettingen, Germany. 2Developmental Biochemistry, University Medical Center Goettingen, Goettingen, Germany. 3Molecular Cell Biology, Institute I for Anatomy, University of Cologne Medical School, Cologne, Germany 4Cluster of Excellence-Cellular Stress Response in Aging-Associated Diseases (CECAD), Cologne, Germany *Correspondence: Dr. Julia Christina Gross, Hematology and Oncology/Developmental Biochemistry, University Medical Center Goettingen, Justus-von-Liebig Weg 11, 37077 Goettingen Germany Abstract Protein trafficking in the secretory pathway, for example the secretion of Wnt proteins, requires tight regulation. These ligands activate Wnt signaling pathways and are crucially involved in development and disease. Wnt is transported to the plasma membrane by its cargo receptor Evi, where Wnt/Evi complexes are endocytosed and sorted onto exosomes for long-range secretion. However, the trafficking steps within the endosomal compartment are not fully understood. The promiscuous SNARE Ykt6 folds into an auto-inhibiting conformation in the cytosol, but a portion associates with membranes by its farnesylated and palmitoylated C-terminus. Here, we demonstrate that membrane detachment of Ykt6 is essential for exosomal Wnt secretion.
    [Show full text]
  • The Green Alga Chlamydomonas Reinhardtii: a New Model System To
    THE GREEN ALGA CHLAMYDOMONAS REINHARDTII: A NEW MODEL SYSTEM TO UNRAVEL THE ASSEMBLY PROCESS OF RESPIRATORY COMPLEXES DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By María del Rosario Barbieri Graduate Program in Plant Cellular and Molecular Biology The Ohio State University 2010 Dissertation Committee Professor Patrice P. Hamel, Adviser Professor Iris Meier Professor Erich Grotewold Professor Juan D. Alfonzo ABSTRACT The general purpose of this research is to contribute to a better understanding of the mitochondrial NADH: ubiquinone oxidoreductase (Complex I) and to illustrate the current view of its assembly process. I propose to use the green alga Chlamydomonas reinhardtii as a novel model system to carry out the molecular dissection of Complex I assembly. The main objective is to discover novel genes controlling the assembly process of this multimeric enzyme. Several reasons including patient death at young age, strict regulations, and ethical concerns make the study of Complex I on humans highly difficult. Although traditionally well established model systems such as the fungi Yarrowia lipolytica and Neurospora crassa and human cell lines have proven useful to understand the role of specific subunits in the assembly process, forward genetic approaches leading to discovery of novel assembly factors have been limited by the lack of straightforward screening methodologies (REMACLE et al. 2008). The process of plant Complex I assembly is largely obscure at present, despite the progress achieved in recent years. In plants, similarly to other eukaryotes, there is no simple strategy to approach the issue of assembly.
    [Show full text]
  • A Novel Familial Case of Diffuse Leukodystrophy Related to NDUFV1 Compound Heterozygous Mutations
    Mitochondrion 13 (2013) 749–754 Contents lists available at ScienceDirect Mitochondrion journal homepage: www.elsevier.com/locate/mito A novel familial case of diffuse leukodystrophy related to NDUFV1 compound heterozygous mutations Oscar Ortega-Recalde a,1, Dora Janeth Fonseca a,b,1, Liliana Catherine Patiño a, Juan Jaime Atuesta c, Carolina Rivera-Nieto a, Carlos Martín Restrepo a,b, Heidi Eliana Mateus a, Marjo S. van der Knaap d, Paul Laissue a,b,⁎ a Unidad de Genética, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia b Genética Molecular de Colombia, Departamento de Genética Molecular, Bogotá, Colombia c Centro Dermatológico Federico Lleras Acosta, Bogotá, Colombia d Department of Child Neurology, VU University Medical Center, Amsterdam, The Netherlands article info abstract Article history: NDUFV1 mutations have been related to encephalopathic phenotypes due to mitochondrial energy metabo- Received 13 December 2012 lism disturbances. In this study, we report two siblings affected by a diffuse leukodystrophy, who carry the Received in revised form 25 March 2013 NDUFV1 c.1156C>T (p.Arg386Cys) missense mutation and a novel 42-bp deletion. Bioinformatic and molec- Accepted 27 March 2013 ular analysis indicated that this deletion lead to the synthesis of mRNA molecules carrying a premature stop Available online 4 April 2013 codon, which might be degraded by the nonsense-mediated decay system. Our results add information on the molecular basis and the phenotypic features of mitochondrial disease caused by NDUFV1 mutations. Keywords: Mitochondrial disease © 2013 Elsevier B.V. and Mitochondria Research Society. All rights reserved. Diffuse leukodystrophy NDUFV1 mutations Genetics 1.
    [Show full text]
  • Biogenesis of NDUFS3-Less Complex I Indicates TMEM126A/OPA7 As an Assembly Factor of the ND4-Module
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.22.350587; this version posted October 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Biogenesis of NDUFS3-less complex I indicates TMEM126A/OPA7 as an assembly factor of the ND4-module Running title: NDUFS3-dependent CI disassembly pathway Luigi D’Angelo,1* Elisa Astro,1* Monica De Luise,2 Ivana Kurelac,2 Nikkitha Umesh-Ganesh,2 Shujing Ding,3 Ian M. Fearnley,3 Massimo Zeviani,3,4 Giuseppe Gasparre,2,5 Anna Maria Porcelli,1,6# Erika Fernandez-Vizarra,3,7# and Luisa Iommarini1# 1Department of Pharmacy and Biotechnology (FABIT), University of Bologna, Bologna, Italy 2Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy 3Medical Research Council-Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK 4Venetian Institute of Molecular Medicine, Via Orus 2, 35128 Padova, Italy; Department of Neurosciences, University of Padova, via Giustiniani 2, 35128 Padova, Italy 5Center for Applied Biomedical Research (CRBA), University of Bologna, Bologna, Italy 6Interdepartmental Center of Industrial Research (CIRI) Life Science and Health Technologies, University of Bologna, Ozzano dell'Emilia, Italy 7Institute of Molecular, Cell and Systems Biology, University of Glasgow, Glasgow, UK. *Co-first authors #Co-last authors To whom correspondence should be addressed: Luisa Iommarini Department of Pharmacy and Biotechnology (FABIT) University of Bologna Via Francesco Selmi 3, 40126 Bologna, Italy Tel. +39 051 2091282 e-mail [email protected] Erika Fernandez-Vizarra Institute of Molecular, Cell and Systems Biology University of Glasgow University Avenue Glasgow G12 8QQ, UK Tel.
    [Show full text]
  • WO 2017/070647 Al 27 April 2017 (27.04.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/070647 Al 27 April 2017 (27.04.2017) P O P C T (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, A61K 31/455 (2006.01) C12N 15/86 (2006.01) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, A61K 31/465 (2006.01) A61P 27/02 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, A61K 31/19 (2006.01) A61P 27/06 (2006.01) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, A61K 48/00 (2006.01) A61K 45/06 (2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (21) International Application Number: ZW. PCT/US2016/058388 (84) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of regional protection available): ARIPO (BW, GH, 24 October 2016 (24.10.201 6) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (25) Filing Language: English TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (26) Publication Language: English DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (30) Priority Data: LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 62/245,467 23 October 2015 (23.
    [Show full text]